The EGFR/PI3K/PTEN/Akt/mTORC pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance, cancer initiating cells (CICs) and metastasis. The expression of this pathway is frequently altered in breast and other cancers due to mutations at or aberrant expression of: HER2, EGFR1, PIK3CA, and PTEN as well as other oncogenes and tumor suppressor genes. miRs and epigenetic mechanisms of gene regulation are also important events which regulate this pathway. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathway has been associated with CICs and in some cases resistance to therapeutics. We will review the effects of activation of the EGFR/PI3K/PTEN/Akt/mTORC pathway primarily in breast cancer and development of drug resistance. The targeting of this pathway and other interacting pathways will be discussed as well as clinical trials with novel small molecule inhibitors as well as established drugs that are used to treat other diseases. In this manuscript, we will discuss an inducible EGFR model (v-ERB-B:ER) and its effects on cell growth, cell cycle progression, activation of signal transduction pathways, prevention of apoptosis in hematopoietic, breast and prostate cancer models. © 2014 Elsevier Ltd.
|Titolo:||Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis|
|Data di pubblicazione:||2015|
|Citazione:||Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis / McCubrey JA; Abrams SL; Fitzgerald TL; Cocco L; Martelli AM; Montalto G; Cervello M; Scalisi A; Candido S; Libra M; Steelman LS. - In: ADVANCES IN BIOLOGICAL REGULATION. - ISSN 2212-4926. - 57(2015), pp. 75-101.|
|Appare nelle tipologie:||1.1 Articolo in rivista|